API
< Back to all clusters
[POLITICS] · India · 9 sources

started · updated

India to cap trade margins on cancer drugs amid Supreme Court scrutiny

The Indian government has informed the Supreme Court of its decision to regulate trade margins on specific anti-cancer medicines by capping them at 30 per cent of the maximum retail price (MRP). Solicitor General Tushar Mehta stated that the government will notify a list of applicable cancer drugs, which may be updated periodically based on market developments and public health needs, while excluding inexpensive medications.

In response, a Supreme Court bench comprising Justices Vikram Nath and Sandeep Mehta called for a broader review of pharmaceutical pricing. The court questioned why regulations were limited to cancer drugs and urged the government to examine excessive markups across the wider medical sector, including medical devices.

The bench highlighted significant disparities between supply prices and MRPs, citing examples such as a cardiac stent with an MRP of Rs 25,000 supplied to retailers for Rs 5,000, and a saline drip line with an MRP of Rs 11 sold for Rs 270. The court requested an explanation on how such high margins serve patient interests, while the government emphasized the need to balance affordability with availability and market considerations.

Entities

Government of India · Sandeep Mehta · Supreme Court of India · Tushar Mehta · Vikram Nath